TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03171935

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-Flow Nasal Cannula Oxygenation
Description: High-flow nasal cannula oxygenation will be applied immediately after early extubation, with a gas flow rate of 50 liters per minute and a fraction of inspired oxygen of 1.0 at initiation. The fraction of inspired oxygen will be subsequently adjusted to maintain a peripheral oxygen saturation of 92% or more.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive Positive Pressure Ventilation
Description: Noninvasive positive pressure ventilation will be applied immediately after early extubation, with a noninvasive ventilator (Respironics V60, Philips) using the NIPSV mode at initiation. The fraction of inspired oxygen will be adjusted to achieve SpO2 \>92% with an initial expiratory positive airway pressure (EPAP) of 4 cmH2O. EPAP will be increased gradually in increments of 1-2 cmH2O, up to a maximum of 12 cmH2O, to achieve SpO2 \>96%. Inspiratory positive airway pressure (IPAP) will be initially set at 8 cmH2O and be increased gradually in increments of 1-2 cmH2O according to patients' tolerance to obtain a tidal volume (VT) of 6-8 mL/kg.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional weaning
Description: The patients will undergo conventional weaning protocol. Extubation and subsequent oxygen therapy with venturi mask will be performed after successful spontaneous trial.
Study: NCT03094962

Intervention type: OTHER
Group type: OTHER
Intervention: Motion capture
Description: Capture kinematics of finger movements

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MR scan
Description: Capture MR images of hand and fingers in three postures

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CT scan
Description: Capture CT images of hand and fingers in three postures
Study: NCT02725567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Granules in sachet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Granules in sachet for oral administration.
Study: NCT01585298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTY720
Study: NCT02929719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test.
Description: gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aczone Gel 5%
Description: gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: gel
Study: NCT01539408

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: single dose of 400 mcg misoprostol administered sublingually

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery Manual vacuum aspiration (MVA)
Description: standard surgical treatment
Study: NCT00680147

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: brief informational intervention to promote HPV vaccine acceptance
Description: Teen and parent participants will receive a brief informational intervention that provides basic facts about the HPV vaccine, including the health benefits and three-dose requirements, along with information regarding where to go to receive the vaccination. A coupon for a free HPV vaccination will provided to the parent for use by their teenage daughter.
Study: NCT04263805

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vignette with emphasis on research climate
Description: A vignette describing a dilemma situation for a researcher (e.g. adding an honorary author) with or without a research environment factor (i.e. an environment where other researchers commit detrimental research practice)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vignette with emphasis on research climate
Description: A vignette describing a dilemma situation for a researcher (e.g. adding an honorary author) with or without a research environment factor (i.e. an environment where other researchers commit detrimental research practice)
Study: NCT02987998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin (50mg/m2 IV D1, 8, 29, 36)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide (50mg/m2 IV D1-5, 29-33)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab (200mg IV D1, 21, 42)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation (1.8Gy/D to 45Gy in 25 fractions)
Study: NCT01154270

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: carbon ion boost
Description: 8 fractions carbon ion (8 x 3 GyE C12) therapy followed by 25 fractions of IMRT corresponding to a total dose of approximately 74 GyE. Treatment duration is approximately 61/2-7 weeks
Study: NCT03599336

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Reverse Total Shoulder Arthroplasty (rTSA)
Description: Surgical management will include placement of fracture specific, cemented reverse total shoulder arthroplasty components as per standard surgical care and routine postoperative rehabilitation.

Intervention type: OTHER
Group type: OTHER
Intervention: Nonoperative Treatment
Description: Subjects allocated to the nonoperative treatment arm will maintain sling immobilization for 3 weeks. The sling will be removed for elbow, wrist and hand range of motion (ROM), hygiene, and dressing only. At 3 weeks passive ROM in external rotation (ER) and forward elevation (FE) will be added. At 6 weeks from injury, the sling will be removed and stretching in all planes will be allowed. Use of the arm will be up to a fork/knife/toothbrush only. At 3 months from injury, strengthening will be added. Supervised physical therapy will be offered to patients for use at their discretion, as is current practice.
Study: NCT02749136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preoperative modified FOLFIRINOX and postoperative gemcitabine
Description: * Preoperative mFOLFIRINOX, every 2 weeks, 8 cycles~  * Oxaliplatin IV 85 mg/m2 Day (D) 1~ * Irinotecan IV 180 mg/m2 D1~ * 5-FU continuous IV infusion 2,400 mg/m2 over 46 hours D1-2~ * Leucovorin IV 400 mg/m2 D1~* Postoperative gemcitabine, every 4 weeks, 3-6 cycles - Gemcitabine 1,000 mg/ m2 D1, 8, and 15
Study: NCT01176318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdosteine
Description: capsule 300mg twice daily for 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsule, twice daily for 10 days
Study: NCT04517942

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EVERYbody Project
Description: Brief behavioral intervention (4 hours across two meetings)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video + Expressive Writing
Description: Brief video-based intervention (4 hours across two meetings)
Study: NCT01005368

Intervention type: GENETIC
Intervention: fluorescence in situ hybridization

Intervention type: GENETIC
Intervention: mutation analysis

Intervention type: GENETIC
Intervention: nucleic acid sequencing

Intervention type: GENETIC
Intervention: polymerase chain reaction

Intervention type: GENETIC
Intervention: western blotting

Intervention type: OTHER
Intervention: flow cytometry

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Study: NCT01587118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjunctive asenapine
Description: participants who are not responding fully to antidepressant therapy for PTSD will receive adjunctive asenapine (flexible dosing beginning with 5 mg sublingual once per day, titrated up to 10 mg twice per day, as tolerated) for a total of 12 weeks.
Study: NCT03598881

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment
Study: NCT00263575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EN3267
Description: EN3267 will be available in 100, 200, 300, 400, 600 (two 300 ug tablets), and 800 ug (two 400 ug tablets) doses
Study: NCT01328210

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood letting
Description: blood letting twice within 4 weeks. First blood removal baseline with 400ml of venous blood and second blood removal with 300-400ml according to serum ferritin levels.
Study: NCT03884712

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CalmiGo
Description: The CalmiGo handheld device is a device of similar size to an inhaler that uses guided breathing, aromatherapy and grounding techniques to regulate breathing to bring users a sense of calm and relaxation. The CalmiGo handheld device is being tested in this study to alleviate participants' anxiety and panic attack symptoms.
Study: NCT02781298

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: New Infant Cereal
Description: The infants will start the complementary feeding with the infants cereals of this study, the amount of cereal ingested will be free according to pediatricians recommendations.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: New Infant Cereal
Description: The infants will start the complementary feeding with the infants cereals of this study, the amount of cereal ingested will be free according to pediatricians recommendations.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multicereals Infant Cereal
Description: The infants will start the complementary feeding with the infants cereals of this study, the amount of cereal ingested will be free according to pediatricians recommendations.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multicereals Infant Cereal
Description: The infants will start the complementary feeding with the infants cereals of this study, the amount of cereal ingested will be free according to pediatricians recommendations.
Study: NCT04064294

Intervention type: DRUG
Intervention: Intravenous Infusion
Description: Intravenous levodopa given 1.0 to 1.5 mg/kg/hr from 0930 - 1130 on a single visit day.

Intervention type: DRUG
Intervention: Intravenous Infusion
Description: Intravenous levodopa given 1.0 to 1.5 mg/kg/hr from 0930 - 1130 on a single visit day.

Intervention type: DRUG
Intervention: Intravenous Infusion
Description: Intravenous levodopa given 1.0 to 1.5 mg/kg/hr from 0930 - 1130 on a single visit day.
Study: NCT03749499

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HTN Educational Video
Description: The video will educate participants in arm 2 about high BP, how it is diagnosed, and the importance of treating it to prevent secondary complications.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Visual Echocardiogram Image Clips
Description: Visual clips of age/gender-matched echocardiograms will be used to educate and motivate patients to change their behavior and improve their BP. We have found that real time visualization of cardiac ultrasound images with active discussion of findings is a significant patient motivator and empowerment tool, and was a significant factor in the success of our previous pilot study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobile Health and Remote BP monitoring
Description: All participants randomized to the intervention group will receive an FDA-approved HBPM kit that includes the Nokia wireless (self-inflating) BPM+ monitor and Health Mate mobile app. The app automatically launches when the patient slips on the cuff and turns on the monitor to measure his/her BP. Synced data are automatically uploaded from the mobile app to the iCardia server of our study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Post-Acute Care HTN Transition consultation (PACHT-c)
Description: All participants randomized to the E2 intervention will have a focused consultation with either a clinical pharmacist or an APN. During this consultation, the pharmacist/APN repeats the BP measurement; reviews the screening assessments; and reviews general principles of BP control including nutrition, exercise, and smoking cessation. BP will be managed according to the current published guidelines available at the time of funding regarding initiation of first-line antihypertensive medications. Patients with BP ≥160/100 mmHg may be started on antihypertensive medications by the provider during the consultation if appropriate.
Study: NCT01530386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Lacosamide will be given orally in 50 mg tablets twice a day for 7 days. The dose will increase weekly by 100 mg per day to a target dose of 300 mg per day. Once the target dose of 300 mg per day has been achieved for 9 days, a 2-day tapering of Lacosamide will occur by 100 mg per day.
Study: NCT00984438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCNU Wafer
Description: Implantable during surgical resection into the tumor bed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: IV every 2 weeks for up to one year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV every 2 weeks for up to one year
Study: NCT01363310

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine XR
Description: Dosage form: tablets Day 1-2: 50 mg Day 3-7: 150 mg Day 8-57: either 150 or 300 mg/day (flexible)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Dosage form: capsules Day 1-7: 10 mg Day 8-57: 10 or 20 mg/day (flexible)
Study: NCT05394090

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: saliva stimulation
Description: In 50 patients with ischemic stroke, saliva was the option of a neurologopedic massage of choice
Study: NCT03167177

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Fully human anti-PD-L1 IgG1 lambda monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Recombinant human anti-VEGF IgG1 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: (SP-4-2)-diamminedichloroplatinum(II)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6- pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: 5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Recombinant human anti-PD-1 IgG4 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omega-3-acid ethyl esters
Description: Omega-3-acid ethyl esters

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: radiation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-803
Description: Recombinant human super agonist interleukin-15 (IL-15) complex

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-011
Description: Ad5 \[E1-, E2b-\]-CEA
Study: NCT01801553

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Usual medical care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual medical care
Study: NCT03167177

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-051
Description: Ad5 \[E1-, E2b-\]-Brachyury

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-061
Description: Ad5 \[E1-, E2b-\]-MUC1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6207
Description: Heat-killed S. cerevisiae yeast expressing CEA

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6301
Description: Heat-killed S. cerevisiae yeast expressing the human Brachyury (hBrachyury) oncoprotein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: haNK
Description: NK-92 \[CD16.158V, ER IL-2\] (high-affinity activated Natural Killer cells)
Study: NCT04587583

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WeCareAdvisor
Description: Tailored, internet-based software intended to assess, manage and track behavioral symptoms and their contributing factors and to instruct dementia caregivers in problem solving approaches (tailored strategies for in-home, medication-free behavior management) to address difficult or disruptive behaviors exhibited by the person with dementia. During the testing period participants will refer to the WeCareAdvisor when behavioral challenges occur.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WeCareAdvisor
Description: Tailored, internet-based software intended to assess, manage and track behavioral symptoms and their contributing factors and to instruct dementia caregivers in problem solving approaches (tailored strategies for in-home, medication-free behavior management) to address difficult or disruptive behaviors exhibited by the person with dementia. During the testing period participants will refer to the WeCareAdvisor when behavioral challenges occur.
Study: NCT04195932

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Study: NCT00966030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0974 tablet
Description: MK0974 280 mg tablet in one of two treatment periods

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: MK0974 liquid filled capsule
Description: MK0974 300 mg liquid filled capsule in one of two treatment periods
Study: NCT01425606

Intervention type: OTHER
Intervention: blood test
Description: blood test to measure levels of: sodium, albumin and acid - base status in venous blood.
Study: NCT01623024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 20.000 UI/week for 96 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle counseling
Description: Lifestyle counseling for 96 weeks
Study: NCT01634451

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bespoke on-line sedation education package
Description: A bespoke on-line education package has been developed and will be accessible by all ICU nursing staff. They will have unique logins and the system will track their use and completion of the education package. There is a small multiple choice assessment at the end of the package.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sedation specific outcome process feedback
Description: Using statistical process charts, the data gathered from the Sedation quality Tools (SQATs) completed each shift by the ICU nurses, will be fed back highlighting sedation specific outcomes e.g. number of over sedated days per 1000 ventilator days.
Study: NCT01607528

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Winclove-849
Description: 6 g of Winclove-849 containing Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactococcus lactis W58 at a concentration of 2.5 x 109 cfu/g

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A similar looking and tasting powder with no active substances
Study: NCT00579709

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thymus Tissue for Transplantation
Description: 3 Thymoglobulin doses given prior to thymus tx. Atypical subjects given Cyclosporine (Csa) pre-tx. Desired Csa concentration 180-300ng/ml. If post-tx T cell count remained \<4000/cumm Csa weaned over 8 weeks. If T cell \>4,000/cumm, Csa held at 180-300ng/ml.~Thymus tissue, donor, \& mother of donor were screened for transplant safety. In operating room, thymic slices were transplanted into quadriceps muscle in 1 or both legs.~Subjects had routine blood research immune evaluations. 2-3 months post-tx, open biopsy of allograft. Immune blood studies continued on surviving subjects until January 2010. Biological Mother: Mother provided blood sample used for DNA extraction, to identify/look for maternal T cell presence in recipient pre-tx, and/or for immune testing post-tx.
Study: NCT02914899

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Surveys
Description: Intake surveys recorded demographics, workplace profile, financial profile, health care access, cancer screening behavior, medical history, etc.~Exit surveys asked whether drivers received shared decision making (SDM) counseling, completed LCS (low-dose computed tomography \[LDCT\] scan), had barriers, felt satisfied, etc.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Surveys
Description: Intake surveys recorded demographics, workplace profile, financial profile, health care access, cancer screening behavior, medical history, etc.~Exit surveys asked whether drivers received shared decision making (SDM) counseling, completed LCS (low-dose computed tomography \[LDCT\] scan), had barriers, felt satisfied, etc.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Surveys
Description: Intake surveys recorded demographics, workplace profile, financial profile, health care access, cancer screening behavior, medical history, etc.~Exit surveys asked whether drivers received shared decision making (SDM) counseling, completed LCS (low-dose computed tomography \[LDCT\] scan), had barriers, felt satisfied, etc.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Navigation
Description: CHWs facilitated SDM and LCS for drivers, providing navigation ( finding a PCP, scheduling appointments, assisting with insurance, etc.), following up on results and next steps.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Navigation
Description: CHWs facilitated SDM and LCS for drivers, providing navigation ( finding a PCP, scheduling appointments, assisting with insurance, etc.), following up on results and next steps.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focus groups
Description: Gained drivers' perspectives on adapting the community health worker (CHW) model to facilitate lung cancer screening (LCS).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-depth interviews
Description: Interviews with Chinese livery bases elicited perspectives on adapting the CWH model for the drivers' occupational environment.~Interviews with PCPs, clinic directors, etc. serving Chinese communities provided insight into adapting the CHW model within the health care context.
Study: NCT04164862

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AccuVein AV400 Device Versus Ultrasound-guided Cannulation
Description: Accuvein AV400 device versus Ultrasound guided cannulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AccuVein AV400 Device Versus Ultrasound-guided Cannulation
Description: Accuvein AV400 device versus Ultrasound guided cannulation